Early cancer detection method

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

436536, 436537, 436538, 436539, 436540, 436541, 436542, 436547, 436548, 436804, 436813, 935100, 935102, 935104, 935106, 935108, G01N 3353

Patent

active

046877339

ABSTRACT:
The invention relates to a method of testing for the presence of cancer. An antibody is produced which contains antibodies specific to a modified nucleoside component. The antibody is admixed with a body fluid drawn from a subject mammal. An immunoassay is performed on the admixture to quantify an amount of cancer associated nucleoside present in the fluid and reactive with the antibody.

REFERENCES:
Terry et al., Carcinoembryonic Antigen: Characterization and Clinical Applications, Transplant Rev., 20: 100-129, 1974.
Weissmann et al., The Purine Bases of Human Urine. II. Semiquantitative Estimation and Isotope Incorporation. J.Biol. Chem. 224: 423-434, 1957.
Mandel et al., The Biosynthesis of Methylated Bases in Ribonucleic Acid. Biochemistry 2: 555-560, 1963.
Mandel et al., Origin of Urinary Methylated Purines. Nature 209: 586-588, 1966.
Gehrke et al., Quantitative High-Performance Liquid Chromatography of Nucleosides in Biological Materials. J. Chromatogr. 150: 455-475, 1978.
Hartwick et al., Identification and Quantitation of Nucleosides, Bases, and Other UV-Absorbing Compounds in Serum, Using Reversed Phase High-Performance Liquid Chromatography. J. Chromatogr. 186: 647-658, 1979.
Speer et al., tRNA Breakdown Products as Markers for Cancer. Cancer 44: 2120-2123, 1979.
Trewyn et al., Elevated Nucleoside Execretion by Patients with Nasopharyngeal Carcinoma: Preliminary Diagnostic/Prognostic Evaluations. Cancer 49: 2513-2517, 1982.
Heldman et al., Differential Execretion of Modified Nucleosides in Adult Acute Leukemia. Blood 61: 291-296, 1983.
Heldman et al., Urinary Excretion of Modified Nucleosides in Chronic Myelogenous Leukemia. J. Lab. Clin. Med. 101: 783-792, 1983.
Heldman et al., Relationship of Urinary Excretion of Modified Nucleosides to Disease Status in Childhood Acute Lymphoblastic Leukemia, J Natl. Cancer Inst. 71: 269-273, 1983.
Levine et al., Serum Levels of N.sup.2,N.sup.2 -Dimethylguanosine and Pseudouridine as Determined by Radioimmunoassay for Patients with Malignancy. J. Natl. Cancer Inst. 54: 341-343, 1975.
Vold, Radioimmunoassays for the Modified Nucleosides N-[9-(.beta.-D-Ribofuranosyl) Purin-6-Ylcarbamoyl]-L-Threonine and 2-Methylthioadenosine. Nucleic Acids Res. 7: 193-204, 1979.
Vold et al., Urine Levels of N-[9-(.beta.-D-Ribofuranosyl) Purin-6-Ylcarbamoyl]-L-Threonine, N.sup.6 -(.DELTA..sup.2 -Isopentenyl) Adenosine, and 2'-O-Methylguanosine as Determined by Radioimmunoassay for Normal Subjects and Cancer Patients. Cancer Res. 42: 5265-5269, 1982.
Woodsworth et al., Characterization of Monoclonal Antibodies Specific for Isopentenyl Adenosine Derivatives Occurring in Transfer RNA. Biochem. Biophys. Res. Commun. 114: 791-796, 1983.
Erlanger, B. F., et al., Antibodies Specific for Ribonucleosides and Ribonucleotides and Their Reation with DNA, Proc. Natl. Acad. Sci. U.S., 52:68-74 (1964).
Inouye, H., et al., Anti-Inosine Antibodies, Biochem. Biophys. Acta., 240; 596-603 (1971).
Farr, R. S., A Quantitative Immunochemical Measure of the Primary Interaction Between I*BSA and Antibody, J. Infec. Dis. 103: 239-262 (1958).
Muller, R., Calculation of Average Antibody Affinity in Antihapten Sera from Data Obtained by Competitive Radioimmunoassay, J. Immunol Meth., 34: 345-352 (1980).
Fishbein, A., et al., Urinary Excretion of Modified Nucleosides in Patients with Malignant Mesothelioma, Cancer Research 43, 2971-2974, (Jun. 1983).
Waalkes, T. P., et al., Urinary Excretion by Cancer Patients of the Nucleosides N.sup.2, N.sup.2 -Dimethylguanosine, 1-Methylinosine, and Pseudouridine, J. Natl. Cancer Inst., 51: 271-274, 1973.
Tormey, D. C., et al., Biological Markers in Breast Carcinoma-Clinical Correlations with Pseudouridine, N.sup.2, N.sup.2 -Dimethylguanosine and 1-Methylinosine, Journal of Surgical Oncology 14:267-273 (1980).
Rasmuson, T., et al., Evaluation of Carcinoembryonic Antigen, Tissue Polypeptide Antigen, Placental Alkaline Phosphatase, and Modified Nucleosides as Biological Markers in Malignant Lymphomas, Resent Results in Cancer Research, vol. 84, Springer-Verlag Berlin, Heidelberg, 1983.
Gehrke, C. W., et al., Patterns of Urinary Excretion of Modified Nucleosides, Cancer Research 39, 1150-1153, Apr. 1979.
Borek, E., et al., New Applications of Urinary Nucleoside Markers, Recent Results in Cancer Research, vol. 84, Springer-Verlag Berlin, Heidelberg, 1983.
Clark, I., et al., Comparison of Urinary Modified Nucleosides and Bases in Rats with Hepatomas and Nephroblastomas, Recent Results in Cancer Research, vol. 84, Springer-Verlag Berlin, Heidelberg, 1983.
Waalkes, T. P., et al., The Urinary Excretion of Nucleosides of Ribonucleic Acid by Patients with Advance Cancer, Cancer 36: 390-398, 1975.
Hartwick, R. A., et al., Identification and Quantitation of Nucleosides, Bases and Other UV-Absorbing Compounds in Serum, Using Reversed Phase High-Performance Liquid Chromatography, J. Chromatog., 186: 659-676, 1979.
Thomale, J., et al., Elevated Urinary Excretion of RNA Catabolities as an Early Signal of Tumor Development in Mice, Cancer Letters, 15: 149-159, 1982.
Waalkes, T. P., et al., Modified Ribonucleosides as Biological Markers for Patients with Small Cell Carcinoma of the Lung, Eur. J. Cancer Clin. Oncol. vol. 18, No. 12, 1267-1274, 1982.
Borek, E., et al., Urinary Nucleic Acid Breakdown Products as Markers for Trophoblastic Diseases, Am. J. Obstet. Gynecol. 146: 906, 1983.
Fink, K., et al., Urinary Purines and Pyrimidines in Normal and Leukemic Subjects, Archives of Biochemistry and Biophysics, 126, 27-33, 1968.
Weissmann, B., et al., The Purine Bases of Human Urine, I. Separation and Identification, J. Biol. Chem. 224: 407-421 (1956).
Yu, T. F., et al., On the Biosynthesis of Uric Acid from Glycine-N.sup.15 in Primary and Secondary Polycythemia, Amer. J. of Med. vol. 21(6): 901-917, Dec. 1956.
Heldman et al., Urinary Excretion of Modified Nucleosides in Chronic Myelogenous Leukemia. Proc. Amer. Soc. Clin. Oncology 1:6, 1982.
Heldman et al., Relationship of Modified Nucleoside Excretion to Disease Status in Childhood Acute Lymphoblastic Leukemia, Blood 60: 128a, 1982.
Heldman et al., Differential Excretion of Modified Nucleosides in Adult Acute Leukemia, Blood 60: 129a, 1982.
Lutter et al., Elevated Excretion of Modified Nucleosides in Non-Hodgkins Lymphomas, Blood 60: 147a, 1982.
Trewyn et al., Alterations in tRNA Metabolism as Markers of Neoplastic Transformation In: Biochemical and Biological Markers of Neoplastic Transformation (P. Chandra, ed) pp. 263-276, Plenum Publishing Corp., New York, 1983.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Early cancer detection method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Early cancer detection method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Early cancer detection method will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1117770

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.